Pfiz­er drops 10 mg dose of best-sell­ing Xel­janz as study spot­lights car­dio safe­ty is­sue, high­er rate of deaths

One of Pfiz­er’s top up-and-com­ing rev­enue pro­duc­ers has run in­to a se­ri­ous safe­ty is­sue dur­ing a post-mar­ket­ing study. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.